Literature DB >> 22414883

Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

Ronald I Clyman1, James Couto, Gail M Murphy.   

Abstract

Although a moderate-sized patent ductus arteriosus (PDA) needs to be closed by the time a child is 1-2 years old, there is great uncertainty about whether it needs to be closed during the neonatal period. Although 95% of neonatologists believe that a moderate-sized PDA should be closed if it persists in infants (born before 28 weeks) who still require mechanical ventilation, the number of neonatologists who treat a PDA when it occurs in infants who do not require mechanical ventilation varies widely. Both the high likelihood of spontaneous ductus closure and the absence of randomized controlled trials, specifically addressing the risks and benefits of neonatal ductus closure, add to the current uncertainty. New information suggests that early pharmacologic treatment has several important short-term benefits for the preterm newborn. By contrast, ductus ligation, while eliminating the detrimental effects of a PDA on lung development, may create its own set of morbidities that counteract many of the benefits derived from ductus closure. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22414883      PMCID: PMC3305915          DOI: 10.1053/j.semperi.2011.09.022

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  104 in total

Review 1.  The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials.

Authors:  D B Knight
Journal:  Semin Neonatol       Date:  2001-02

2.  Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.

Authors:  B Schmidt; P Davis; D Moddemann; A Ohlsson; R S Roberts; S Saigal; A Solimano; M Vincer; L L Wright
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

3.  Echocardiographic prediction of patent ductus arteriosus in need of therapeutic intervention.

Authors:  S Harling; I Hansen-Pupp; A Baigi; E Pesonen
Journal:  Acta Paediatr       Date:  2010-10-13       Impact factor: 2.299

4.  Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment.

Authors:  Nami Jhaveri; Anita Moon-Grady; Ronald I Clyman
Journal:  J Pediatr       Date:  2010-09       Impact factor: 4.406

5.  Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.

Authors:  J Patel; I Roberts; D Azzopardi; P Hamilton; A D Edwards
Journal:  Pediatr Res       Date:  2000-01       Impact factor: 3.756

6.  Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus.

Authors:  M Pezzati; V Vangi; R Biagiotti; G Bertini; D Cianciulli; F F Rubaltelli
Journal:  J Pediatr       Date:  1999-12       Impact factor: 4.406

7.  Patterns of gene expression in the ductus arteriosus are related to environmental and genetic risk factors for persistent ductus patency.

Authors:  Nahid Waleh; Ryan Hodnick; Nami Jhaveri; Suzanne McConaghy; John Dagle; Steven Seidner; Donald McCurnin; Jeffrey C Murray; Robin Ohls; Ronald I Clyman
Journal:  Pediatr Res       Date:  2010-10       Impact factor: 3.756

8.  Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse.

Authors:  J Reese; B C Paria; N Brown; X Zhao; J D Morrow; S K Dey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

9.  Outcome of children in the indomethacin intraventricular hemorrhage prevention trial.

Authors:  L R Ment; B Vohr; W Allan; M Westerveld; S S Sparrow; K C Schneider; K H Katz; C C Duncan; R W Makuch
Journal:  Pediatrics       Date:  2000-03       Impact factor: 7.124

10.  Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2.

Authors:  C D Loftin; D B Trivedi; H F Tiano; J A Clark; C A Lee; J A Epstein; S G Morham; M D Breyer; M Nguyen; B M Hawkins; J L Goulet; O Smithies; B H Koller; R Langenbach
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

View more
  60 in total

1.  Diagnosis and Management of Patent Ductus Arteriosus.

Authors:  Maria Gillam-Krakauer; Jeff Reese
Journal:  Neoreviews       Date:  2018-07

2.  Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU.

Authors:  T D Nelin; E Pena; T Giacomazzi; S Lee; J W Logan; M Moallem; R Bapat; E G Shepherd; L D Nelin
Journal:  J Perinatol       Date:  2017-06-15       Impact factor: 2.521

3.  Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants.

Authors:  Jonathan L Slaughter; Patricia B Reagan; Thomas B Newman; Mark A Klebanoff
Journal:  JAMA Pediatr       Date:  2017-03-06       Impact factor: 16.193

Review 4.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

Review 5.  The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia.

Authors:  Ronald I Clyman
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

6.  Activation of the EGFR/p38/JNK pathway by mitochondrial-derived hydrogen peroxide contributes to oxygen-induced contraction of ductus arteriosus.

Authors:  Zhigang Hong; Jésus A Cabrera; Saswati Mahapatra; Shelby Kutty; E Kenneth Weir; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2014-06-08       Impact factor: 4.599

7.  Serial echocardiography in very preterm infants: a pilot randomized trial.

Authors:  Sara B DeMauro; Meryl S Cohen; Sarah J Ratcliffe; Soraya Abbasi; Barbara Schmidt
Journal:  Acta Paediatr       Date:  2013-09-13       Impact factor: 2.299

Review 8.  Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus.

Authors:  Mehmet Yekta Oncel; Omer Erdeve
Journal:  World J Clin Pediatr       Date:  2016-02-08

9.  Role of dynamin-related protein 1 (Drp1)-mediated mitochondrial fission in oxygen sensing and constriction of the ductus arteriosus.

Authors:  Zhigang Hong; Shelby Kutty; Peter T Toth; Glenn Marsboom; James M Hammel; Carolyn Chamberlain; John J Ryan; Hannah J Zhang; Willard W Sharp; Erik Morrow; Kalyani Trivedi; E Kenneth Weir; Stephen L Archer
Journal:  Circ Res       Date:  2013-01-18       Impact factor: 17.367

10.  Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus.

Authors:  James I Hagadorn; Elizabeth A Brownell; Jennifer M Trzaski; Kendall R Johnson; Shabnam Lainwala; Brendan T Campbell; Katherine W Herbst
Journal:  Pediatr Res       Date:  2016-08-10       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.